Oling, Reysel Vienne -.
HRN: 17-52-82 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
04/10/2024
CEFUROXIME 750MG (VIAL)
04/10/2024
04/17/2024
IV
210mg
Q8H
S/P Excision Of Submandibular Mass
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes